Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| May 1, 26 | Maraldo David R. | officer: EVP & Pres. MMD | 0 | — | |
| Sep 30, 26 |
| Seidman Christine E |
| director |
| A-Award |
| 56 |
| — |
| Sep 30, 26 | Karsanbhai Surendralal Lanca | director | A-Award | 112 | — |
| Sep 30, 26 | Coe Mary Ellen | director | A-Award | 206 | — |
| Sep 1, 26 | Gupta Gaurav K | officer: EVP, CIDO | 0 | — |
| Aug 7, 27 | Gupta Gaurav K | officer: EVP, CIDO | 19,443 | — |
| Aug 13, 26 | Guindo Chirfi | officer: EVP, Access, Policy & Comms | S-Sale | 10,000 @ $135.00 | $1.35M |
| Aug 12, 26 | Zachary Jennifer | officer: EVP, General Counsel | M-Exempt | 13,433 @ $84.71 | $1.14M |
Stock news · updated daily
Merck CEO Rob Davis joins 'Squawk on the Street' to discuss leaked data of melanoma vaccine trials, the drop off the company's stock price and more.
Beneath the chaos surrounding Moderna and Merck's latest data on their personalized cancer vaccine, oncologists see something else: an important milestone in melanoma treatment. The companies on Thursday released detailed results from a Phase 3 trial on their mRNA-based shot after partial data leaked on social media platforms earlier that day.
Full late-stage results for the personalized melanoma vaccine from Moderna (NASDAQ:MRNA | MRNA Price Prediction) and Merck (NYSE:MRK) came back positive, yet the selling hasn't stopped. Those numbers landed short of the loftiest hopes built into a long rally.
Brookstone Capital Management boosted its holdings in Merck and Co., Inc. (NYSE: MRK) by 15.2% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 150,102 shares of the company's stock after acquiring an additional 19,812 shares during the quarter.
Moderna shares are taking a hit after the leak of highly anticipated details about the company's vaccine for the skin cancer melanoma.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ: MRNA) today announced detailed positive recurrence-free surv
RAHWAY, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ: MRNA) today announced detailed positive recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) results from the Phase 3 INTerpath-001 trial evaluating intismeran autogene (intismeran; V940 or mRNA-4157), a novel investigational mRNA-based individualized neoantigen therapy (INT) being jointly developed by Merck and Moderna, in c.
Moderna Inc. (NASDAQ:MRNA) stock plunged more than 25% Thursday after the alleged leak of an ESMO 2026 conference abstract raised concerns about the effectiveness of its experimental personalized melanoma vaccine.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 4, 2026 | -0.27 | -0.13 | Beat 51.9% | $16.61B |
| Apr 30, 2026 | -1.47 | -1.28 | Beat 12.9% | $16.29B |
| Feb 3, 2026 | 2.01 | 2.04 | Beat 1.5% | $16.40B |
| Oct 30, 2025 | 2.36 | 2.58 | Beat 9.3% | $17.28B |
| Jul 29, 2025 | 2.03 | 2.13 | Beat 4.9% | $15.81B |
| Apr 24, 2025 | 2.13 | 2.22 | Beat 4.2% | $15.53B |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 3/A | Oct 22, 2026 | 2026-10-22 16:05:53 | View |
| 25-NSE | Oct 15, 2026 | 2026-10-15 09:29:37 | View |
| 8-K | Oct 13, 2026 | 2026-10-13 12:36:57 | View |
| 4 | Oct 1, 2026 | 2026-10-01 13:52:06 | View |
| 4 | Oct 1, 2026 | 2026-10-01 13:50:13 | View |
| 4 | Oct 1, 2026 | 2026-10-01 13:48:16 | View |
| 3 | Sep 1, 2026 | 2026-09-01 15:40:40 | View |
| 4 | Aug 13, 2026 | 2026-08-13 17:02:25 | View |
| 4 | Aug 13, 2026 | 2026-08-13 16:11:35 | View |
| 4 | Aug 12, 2026 | 2026-08-12 16:10:52 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | MRK | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 114.8x | 168.4x · sector 20.7x | Elevated |
| Forward P/E (FY26E) | 54.6x | EPS est. 2.65 | Discount |
| Price / Book | 8.5x | 5.8x | Elevated |
| Price / Sales | 5.4x | 4.3x | Elevated |
| EV / EBITDA | 29.0x | 18.4x | Elevated |
| Return on equity | 6.6% | — | Weak |
| Gross margin | 75.4% | 72.8% | In line |
| Debt / Equity | 1.29 | 0.87 | Moderate |
| Piotroski / Altman Z | 5/9 | Z 3.99 | Safe zone |
Discounted cash flow model
1255 daily bars · split adjusted
FY2025 · 10-K disclosure
FY2025 · 10-K disclosure
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 48.47 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 58.43 | Oscillator | Neutral |
| Williams %R (14) | -62.00 | Oscillator | Neutral |
| MACD (12, 26, 9) | 0.39 (Hist 0.17) | Oscillator | Strong Buy |
| Average Directional Index (14) | 17.08 (+DI 26.5 / -DI 15.9) | Trend | Neutral |
Current price $144.63
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| EMA 20 | 145.77 | MA | Sell |
| SMA 20 | 145.16 | MA | Sell |
| EMA 50 | 143.44 | MA | Buy |
| SMA 50 | 146.63 | MA | Sell |
| SMA 200 | 125.86 | MA | Strong Buy |
| Oct 12, 26 |
| Citigroup |
| maintain |
| Neutral |
| Neutral |
| Oct 12, 26 | RBC Capital | maintain | Sector Perform | Sector Perform |
| Oct 8, 26 | Cantor Fitzgerald | maintain | Neutral | Neutral |
| Oct 7, 26 | Morgan Stanley | maintain | Overweight | Overweight |
| Oct 5, 26 | JP Morgan | maintain | Overweight | Overweight |
| Sep 29, 26 | Scotiabank | maintain | Sector Outperform | Sector Outperform |
| Sep 10, 26 | HSBC | maintain | Buy | Buy |
| Sep 9, 26 | Leerink Partners | maintain | Outperform | Outperform |
| Sep 8, 26 | Guggenheim | maintain | Buy | Buy |